

Poster presentation

Open Access

## **P05-05. Enhanced immunogenicity of HIV-1 envelope glycoprotein trimers fused to CD40 ligand**

M Melchers<sup>1</sup>, K Matthews<sup>2</sup>, T van Montfort<sup>1</sup>, I Bontjer<sup>1</sup>, D Eggink<sup>1</sup>, R de Vries<sup>1</sup>, E Michael<sup>2</sup>, K David<sup>2</sup>, JP Moore<sup>2</sup>, B Berkhout<sup>1</sup> and RW Sanders\*<sup>2</sup>

Address: <sup>1</sup>Academic Medical Center, Amsterdam, Netherlands and <sup>2</sup>Microbiology and Immunology, Weill Medical College of Cornell University, New York, USA

\* Corresponding author

from AIDS Vaccine 2009  
Paris, France. 19–22 October 2009

Published: 22 October 2009

*Retrovirology* 2009, **6**(Suppl 3):P81 doi:10.1186/1742-4690-6-S3-P81

This abstract is available from: <http://www.retrovirology.com/content/6/S3/P81>

© 2009 Melchers et al; licensee BioMed Central Ltd.

### **Background**

Subunit vaccines are often poor immunogens compared to live-attenuated and whole-inactivated virus vaccines. One reason is the lack of costimulatory signals provided by various components of live-attenuated and whole-inactivated vaccines. Here we improved the immunogenicity of the HIV-1 envelope glycoproteins (Env) by direct fusion to a costimulatory molecule, CD40 ligand (CD40L), which we term 'cis-adjuvant'. The rationale was to target the antigen directly to dendritic cells (DC) and B cells, while at the same time activating these cells.

### **Methods**

Chimeric Env-CD40L containing a stabilized gp140 (SOSIP.R6), a GCN4-based trimerization domain, and the globular domain of human or mouse CD40L, was constructed and transiently expressed in 293T cells. The expression and trimerization was analyzed by SDS-PAGE, BN-PAGE and analytical size exclusion chromatograph. The interaction with ligands and neutralizing antibodies was monitored by immunoprecipitation. The immunomodulatory properties on monocyte-derived immature DCs were tested. After incubation with immature monocyte-derived DC, the upregulation of DC maturation markers was monitored by FACS and the secretion of cytokines was analyzed by ELISA. Mice were immunized with plasmids encoding gp140 or gp140-CD40L via intramuscular or dermal (gene gun) routes and the Env-specific antibody response was followed by ELISA.

### **Results**

The trimeric gp140-CD40L construct interacted with CD4 and CD40 and was recognized by neutralizing antibodies. Moreover, gp140-CD40L was able to activate dendritic cells and induce secretion of cytokines from these cells. Importantly, gp140-CD40L induced ~6-10-fold higher gp120-specific antibody titers than gp140 alone in mice vaccinated via intramuscular or dermal DNA immunization routes.

### **Conclusion**

Fusion to CD40L enhanced the immunogenicity of HIV-1 Env trimers. Antigen targeting via CD40L or other 'cis-adjuvants' may have wider applicability in subunit vaccine development.